Skip to content
Open access

Does PD‐L1 Combined Positive Score Have Prognostic Value in Hypopharyngeal Squamous Cell Carcinoma? A Retrospective Cohort Study

Oct 2026 · Laryngoscope Investigative Otolaryngology · Vol 11 · 0 citations · 41 references
Medicine

TL;DR

Whether pretreatment PD‐L1 CPS is prognostically associated with survival in patients with HPSCC treated nonsurgically and without immunotherapy is determined and overall survival in actively treated patients without distant metastases is assessed.

Abstract

The aim of this study was to determine whether pretreatment PD‐L1 CPS is prognostically associated with survival in patients with HPSCC treated nonsurgically and without immunotherapy, and to assess overall survival (OS) in actively treated patients without distant metastases according to CPS < 1 versus CPS ≥ 1.

Read PDF

Similar papers

Open access Sep 2026

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real‐world study

A novel prognostic index for patients with locally advanced or metastatic biliary tract cancer treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab is explored and validated.

M. Persano, A. Casadei-Gardini, L. Fornaro et al. · 0 citations
Open access Oct 2026

Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer

This cohort study examines time to next treatment and overall survival associated with initiation of lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) among US patients with metastatic androgen pathway modulator–resistant prostate cancer.

Varun Nandakumar, Y. Jo, M. Ostrowski et al. · 0 citations
Open access Oct 2026

Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma

Perioperative immunotherapy has become the standard of care in patients with high‐risk muscle‐invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).

Satoshi Katayama, Tatsushi Kawada, K. Mori et al. · 1 citation
Open access Sep 2026

Impact of post‐chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children’s Oncology Group AREN0532, AREN0533, and AREN03B2 studies

Improvements in therapy for patients with favorable histology Wilms tumor (FHWT) have relied on refinement of risk stratification for therapeutic assignment through identification of favorable and unfavorable prognostic factors. Although well established in International Society of Pediatric Oncology‐Renal Tumor Study...

N. Evageliou, L. Renfro, K. Vallance et al. · 1 citation · ⚡1
Clinical trial Open access Oct 2026

Blood‐based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG‐GY012

The NRG‐GY012 phase 2 trial evaluated olaparib, cediranib, and the combination in 120 patients with recurrent, persistent, or metastatic endometrial cancer (EC). Predictive and prognostic associations between blood‐based biomarkers and clinical outcomes were assessed.

Andrew B. Nixon, Danielle M. Enserro, David P. Bender et al. · 0 citations
Oct 2026

ASTRUM-006 and the changing landscape of perioperative therapy for gastric cancer.

ASTRUM-006 provides phase 3 evidence that perioperative immune checkpoint inhibition improves event-free survival with Asian SOX-based chemotherapy in PD-L1-positive gastric cancer. Its postoperative chemotherapy-sparing strategy is attractive, although unmasking, event adjudication, and non-R0 or occult metastatic dis...

H. Kim, I. Chau, R. Sundar · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.